Summary. Insulin, specifically substituted at the Phe m position with 3,5-diiodotyrosine, has been tested in several biological and immunological systems. Immunoreactivity was assessed using antisera specific for different parts of the insulin molecule. Biological activity in vitro was estimated on isolated rat fat cells. In vivo bioactivity (hypoglycaemia) and metabolism (metabolic and urinary clearance rates, half-life, apparent distribution space) were measured by infusion of the material into greyhounds. The results indicated that this B l-labelled insulin preparation was biologically fully active and, unlike randomly labelled preparations of iodoinsulin, was metabolised with kinetics indistinguishable from those of the unlabelled hormone. We suggest that this material is a valid tracer for insulin, fulfilling the criteria of high specific activity and biological identity to the native hormone.
Much research on the mode of action and the metabolism of insulin has depended on the use of radioactive derivatives of the hormone. However the validity of i0dine-labelled insulin as a tracer for such studies has been seriously questioned. Reports on the biological activity of various preparations are conflicting. Perhaps the clearest evidence against the biological identity of iodinated and native insulin is the work of Ooms et al. [1, 2] on the in vivo metabolism of the hormone. In measurements of metabolic clearance rates, unlike bioassays, the fate 1 Hoechst AG, D-6000 Frankfurt/M-Hfchst of iodine-labelled molecules can be examined independently of the uniodinated species present in all heterogeneous preparations. Ooms' results indicated clearly that irrespective of the degree of iodination the metabolic clearance rate of iodoinsulin was both reduced and altered in character.
The position of iodine incorporation into the tyrosine and histidine residues of insulin is not defined in most iodination methods. Variations in conditions may alter the susceptibilities of particular residues for substitution [3] [4] [5] , however the A14 and/or A19 tyrosines are predominantly iodinated. A19 is an invariant residue in the insulin sequence [6] and is thought to be in an area important in maintaining the structural integrity necessary for insulin action. One way of making a valid tracer for insulin would be by labelling specifically a region of the molecule that is not involved in activity.
Insulin modified at the B-1 position appears to retain normal biological [7, 8] and metabolic characteristics (personal observation). Kraft et al. [9] replaced Phe m with p-iodophenylalanine and this preparation was 62-73% active in vitro [10] . Halban et al.
[11] prepared a tritiated Phe m derivative which showed full biological activity initially but appeared to deteriorate on storage. Furthermore it was of relatively low specific activity. We have examined the biological activity, immunoreactivity and the kinetics of metabolism of insulin substituted at Phe B1 with 3,5 diiodo 127 tyrosine.
Materials and Methods
The iodinated compound studied was prepared by replacing the phenylalanine at the N terminus of the B chain of porcine insulin with 3,5-di127I-tyrosine (overall yield 10-15%) [12] . The reference stand- 
Kjeldahl Analysis
The nitrogen contents of diiodoinsulin and of bovine insulin (• recrystallised, Boots Co. Ltd., Nottingham) were estimated by micro-Kjeldahl analysis [13] .
Immunoreactivity
Immunoreactivity was assessed using a double-antibody radioimmunoassay [14] and two different antisera known to react with different sites on the insulin molecule [15] . Antiserum 12 was insensitive to modifications in the B-1 region but reacted with lower affinity to analogues modified in the A1, B30 area. Conversely, GP5 antiserum distinguished insulins modified in the B-1 region from native insulin but was relatively insensitive to alterations elsewhere in the molecule. [16] of the method of Rodbell [17] from the epididymal fat tissue of 100-120 g male Wistar rats. Aliquots of the cell pool were incubated in Krebs-Ringer bicarbonate buffer containing human serum albumin (10 g 1-1), glucose (0.55 mmol 1-1) and 0.1 ~tCi 3-3H-glucose (Radiochemical Centre, Amersham) in 1.0 ml incubates. Dilutions of insulin and diiodoinsulin were included in the assay and incorporation of tritium into toluene-extractable lipids determined [18] . Data from the linear portion of the log dose-response curves were analysed using parallel-line bioassay techniques as described by Finney [19] .
b) In vivo: Experiments were performed in intact,
anaesthetised greyhounds by a priming-dose, constant infusion technique [20] based on that used in humans by S6nksen et al. [14] . Standard bovine insulin or diiodoinsulin were infused at equimolar 
Metabolism
The greyhound experiments described above allowed calculations of the parameters of the in vivo metabolism of insulin and diiodoinsulin [14] . Serum and urine concentrations of the two materials were measured by radioimmunoassay using antiserum 12 and standards of bovine or diiodoinsulin. Urine samples were dialysed against 0.05 mol 1-2 phosphate buffer, pH 7.5 for twenty four hours before measurement. The metabolic and urinary clearance rates were calculated at the four steady state concentrations of hormone achieved, and the half-decay time (Yl/2) and apparent distribution space derived.
Results

Micro-Kfeldahl
The nitrogen content of the diiodoinsulin preparation was found to be 14.6% (mean of 3 assays). This compares with a nitrogen content of 14.7% for the bovine insulin.
Irnmuno reactivity
Diiodoinsulin was indistinguishable from standard porcine insulin in its ability to compete with 125I-insulin for binding to antiserum 12 ( Fig. 1, top) . The lower graph of Figure 1 illustrates that the diiodinated derivative was considerably less effective than insulin in competing with labelled insulin for binding to GP5 antiserum. This is consistent with an insulin modified in the B 1 position.
Bioactivity
The relative abilities of porcine insulin and diiodoinsulin to stimulate rat fat cell lipogenesis are shown in Figure 2 . The two preparations appeared identical. Calculation of the results from three separate experiments indicated that the diiodo derivative had a mean potency 108.8% that of insulin (95% fiducial limits 129.9-96.4%). Similarly the material had full biological activity in vivo when assessed in three dogs. The fall in plasma glucose concentration on infusion of diiodoinsulin was indistinguishable from that caused by insulin (Fig. 3) .
Metabolism
Calculation of the metabolic clearance rate at four different steady-state concentrations (Fig. 4) indicated that the metabolism of diiodoinsulin and the native material were indistinguishable. As with unlabelled insulin, the metabolic clearance rates fell with increasing plasma concentrations of the derivative and the values from all three experiments lay within the normal range for unlabelled insulin. In addition, T1/2 and apparent distribution space were not significantly different for the two materials. Urinary clearance showed no tendency to change with k increasing plasma concentration and again, insulin and diiodoinsulin were indistinguishable in this respect (Table 1) .
Discussion
Evidence that iodinated insulins are biologically active and metabolised normally has been contradictory. Since the demonstration of a direct relation-
ship between the degree of iodination and either loss of bioactivity [21, 22] , or reduction in metabolism [1, 2, 23] it has been common practice to use "lightly" iodinated insulin in tracer studies. However Arquilla et al. [24] demonstrated that the bioactivity of insulin labelled with one iodine atom per molecule or less was still impaired. Similarly, Ooms [1, 2] reported a reduced metabolic clearance rate and some loss of saturability of clearance of insulin labelled with less than 0.2 atoms per mole.
Randomly iodinated insulin preparations consist of a mixture of molecules with varying degrees of substitution and, in all but heavily iodinated preparations, there is a significant proportion of molecules that are unsubstituted. Great care is required lest the biological activity of the preparation is ascribed to the iodinated insulin when it is in fact due to the unlabelled molecules present. In an attempt to overcome this problem Freychet et al. [25] purified monoiodoinsulin from a crude iodination mixture and demonstrated full activity of the product in vitro. However others have found purified monoiodoinsulins to be only partially active [26] [27] [28] or completely inactive [29] . The biological activities of some of these monoiodoinsulin preparations [26, 27, 29] correlated directly with the percentage of their radioactivit~r in the A14 position, consistent with the observation by Garratt et al. [30] that iodination of A19 resulted in a reduced activity of the hormone. However the preparation of Linde and Hansen [28] showed the reverse trend. The monoiodoinsulin of Sodoyez et al. [31] was fully active biologically and in receptor binding and may prove to be a valid insulin tracer.
Thus the biological activities of purified monoiodoinsulins prepared by random iodination methods appear to differ, possibly in relation to the amount of iodine incorporated into A19 tyrosine, and it is impossible to escape from the conclusion that these materials fail to meet all the requirements for a valid tracer for insulin. The selective approach described here overcomes the inherent problems of random iodination. The immunoreactivity results indicated a pure "insulin" preparation modified at the B-1 position. The substituted material was fully active in an in viva and an in vitro bioassay and exhibited normal metabolic and urinary clearance, halflife and apparent distribution space in dogs. When 125Iodine is used in the synthesis, this derivative will have the high specific activity required for physiological studies, (maximum theoretical specific activity = 733 ~tCi/~tg). (3,5-diiodotyrosine) m insulin therefore fulfills all the necessary criteria for a valid tracer for insulin.
It may be argued that it is valid to use a tracer whose properties are not all identical to those of the native hormone in radioimmunoassays or receptor binding assays where the relative abilities of two unlabelled species in displacing a radioactive derivative are being compared. However in studies on the mode of action or the metabolism of a hormone, the behaviour of the labelled species is being examined directly and it is essential that it behaves identically to the native hormone. It will be interesting to note whether the parameters of many mathematical models for insulin metabolism, or the calculations of insulin receptor numbers and binding characteristics will be altered when a valid tracer is used in their measurement.
